Edition:
United Kingdom

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

21.73USD
8:59pm GMT
Change (% chg)

$-1.34 (-5.81%)
Prev Close
$23.07
Open
$23.22
Day's High
$23.22
Day's Low
$21.68
Volume
73,708
Avg. Vol
74,013
52-wk High
$37.45
52-wk Low
$19.62

Select another date:

Tue, Dec 4 2018

Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

UPDATE 2-Revance Therapeutics' Botox rival succeeds in late-stage trial

Dec 4 A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

Revance Therapeutics' frown lines treatment succeeds in late-stage trial

Dec 4 Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

Select another date: